ResMed (NYSE: RMD) reported Q1 EPS of $0.58, $0.01 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $411.6 million versus the consensus estimate of $406.29 million.

For earnings history and earnings-related data on ResMed (RMD) click here.